title: Effect of spirapril on left ventricular hypertrophy due to volume overload in rats.
abstract: The effect of the angiotensin-converting enzyme (ACE) inhibitor spirapril on structural and functional parameters of volume-overloaded rat hearts was evaluated in a time-course study. Left ventricular hypertrophy (LVH) was induced by graded disruption of the aortic valve in male Wistar rats. Four weeks later, structural (LV mass and LV wall thickness) as well as functional parameters [LV end-systolic and end-diastolic volumes, stroke volume (SV), ejection fraction (EF)] were determined in anesthetized animals by magnetic resonance imaging (MRI). The rats were then divided into two groups, one of them receiving spirapril (10 mg/kg/day) in food. LV parameters were evaluated by MRI at 4, 18, 25, and 32 days after treatment was started. MRI analysis before the start of treatment showed that both groups had developed a similar degree of eccentric LV hypertrophy. Similarly, LV wall thickness, end-systolic and end-diastolic volumes, SV, and EF did not differ between the groups. Treatment with spirapril resulted in stable LV weight during the follow-up period of 32 days, whereas the untreated group showed a significant steady increase in heart weight. LV end-diastolic volume, LV end-systolic volume, and SV were smaller in the spirapril group when measured after 25 and 32 days, but only the difference in end-diastolic volume reached statistical significance. LV wall thickness and EF were not affected by spirapril. After the last MRI determinations, blood pressure (BP) and the response to angiotensin I (ANGI) were measured in conscious animals. Systolic BP (SBP) and mean arterial pressure (MAP) were significantly lower in spirapril-treated rats, and the dose-response curve to ANGI was shifted to the right.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Sandoz Pharma Ltd., Basel, Switzerland.
authors.forename: K
authors.initials: K
authors.lastname: Umemura
authors.forename: W
authors.initials: W
authors.lastname: Zierhut
authors.forename: M
authors.initials: M
authors.lastname: Rudin
authors.forename: D
authors.initials: D
authors.lastname: Novosel
authors.forename: E
authors.initials: E
authors.lastname: Robertson
authors.forename: B
authors.initials: B
authors.lastname: Pedersen
authors.forename: R P
authors.initials: RP
authors.lastname: Hof
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006332:Cardiomegaly / Q000517:prevention & control*; D004656:Enalapril / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006352:Heart Ventricles / Q000033:anatomy & histology; D008279:Magnetic Resonance Imaging; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013318:Stroke Volume / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; C052555:spirapril